Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice

BACKGROUND: Metformin, an FDA-approved drug for the treatment of Type II diabetes, has emerged as a promising anti-cancer agent. Other biguanide analogs, including buformin and phenformin, are suggested to have similar properties. Although buformin was shown to reduce mammary tumor burden in carcino...

Descripción completa

Detalles Bibliográficos
Autores principales: Parris, Amanda B., Zhao, Qingxia, Howard, Erin W., Zhao, Ming, Ma, Zhikun, Yang, Xiaohe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307817/
https://www.ncbi.nlm.nih.gov/pubmed/28193239
http://dx.doi.org/10.1186/s13046-017-0498-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307817/
https://www.ncbi.nlm.nih.gov/pubmed/28193239
http://dx.doi.org/10.1186/s13046-017-0498-0

Ejemplares similares